What question did this study set out to answer?

To evaluate the efficacy of moxonidine on blood pressure and metabolic syndrome components in a racially diverse population during routine clinical practice.

January 1, 2013International Journal of HypertensionOpen Access

Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study

View Full Paper

Ask AI

Bookmark

Why the study?

Does moxonidine reduce blood pressure and improve metabolic parameters in patients with uncontrolled essential hypertension and metabolic syndrome?

Key Points

To evaluate the efficacy of moxonidine on blood pressure and metabolic syndrome components in a racially diverse population during routine clinical practice.
Conducted a prospective routine-practice study enrolling consecutive patients with uncontrolled essential hypertension and criteria for metabolic syndrome.
Administered moxonidine (0.2–0.4 mg once daily) for 6 months as monotherapy or as an add-on to existing antihypertensive regimens.
Systolic and diastolic blood pressure decreased by an average of 24.5 ± 14.3 mmHg and 12.6 ± 9.1 mmHg, respectively.
Blood pressure control (<140/90 mmHg) was achieved at significantly higher rates among younger patients, nonpostmenopausal women, and those receiving monotherapy (P < 0.001).
Overall reductions occurred in body weight (-2.1 ± 5.4 kg), fasting plasma glucose (6.8 to 6.2 mmol/L), and triglycerides (2.4 to 2.0 mmol/L), with statistical significance observed in subgroup analyses.

Structured PICO

Does moxonidine reduce blood pressure and improve metabolic parameters in patients with uncontrolled essential hypertension and metabolic syndrome?

Population

Racially diverse population of patients with uncontrolled essential hypertension and criteria for metabolic syndrome encountered in routine medical practice

Intervention

Moxonidine (0.2-0.4 mg once daily) for 6 months, either as monotherapy or as adjunct therapy to current antihypertensive treatment

Outcome

Blood pressure (systolic and diastolic) and aspects of the metabolic syndromesurrogate

Moxonidine therapy significantly reduced blood pressure and showed a trend towards improving metabolic parameters in patients with uncontrolled hypertension and metabolic syndrome.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Moxonidine-associated BP reductions merit randomized trials in metabolic syndrome; leaves open effects on metabolic parameters and outcomes.

Cite This Study

Чазова et al. (2013) studied this question.

synapsesocial.com/papers/6a7057bc31a3df8243289b71 https://doi.org/10.1155/2013/541689

View Full Paper

Ask AI

Bookmark

Implication

Moxonidine-associated BP reductions merit randomized trials in metabolic syndrome; leaves open effects on metabolic parameters and outcomes.

Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider